Ubac

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Липотейхоевая kiselina od komponenti biofilma prianjanje стрептококков uberis, procijediti 5616

Available from:

Laboratorios Hipra, S.A.

ATC code:

QI02AB

INN (International Name):

Streptococcus uberis vaccine (inactivated)

Therapeutic group:

stoka

Therapeutic area:

Imunološki za bovide

Therapeutic indications:

Za aktivna imunizacija zdravih krava i junica, kako smanjiti učestalost kliničkih интрамаммарный infekcija uzrokovana Streptococcus uberis, da se smanjuje broj somatskih stanica i Streptococcus uberis pozitivne kvartal uzoraka mlijeka i smanjiti proizvodnju mlijeka šteta uzrokovana Streptococcus uberis интрамаммарный infekcija.

Product summary:

Revision: 1

Authorization status:

odobren

Authorization date:

2018-07-26

Patient Information leaflet

                                14
B. UPUTA O VMP
15
UPUTA O VMP:
UBAC EMULZIJA ZA INJEKCIJU ZA GOVEDA
1.
NAZIV I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE U PROMET I
NOSITELJA ODOBRENJA ZA PROIZVODNJU ODGOVORNOG ZA PUŠTANJE
SERIJE U PROMET, AKO JE RAZLIČITO
Nositelj odobrenja za stavljanje u promet i proizvođač odgovoran za
puštanje serije
u promet:
LABORATORIOS HIPRA, S.A.
Avda. la Selva, 135
17170- AMER (Girona)
SPAIN
2.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
UBAC emulzija za injekciju za goveda
3.
KVALITATIVNI I KVANTITATIVNI SASTAV DJELATNE(IH) TVARI I DRUGIH
SASTOJAKA
Jedna doza (2 ml) sadrži:
DJELATNA TVAR:
Lipoteikoična kiselina (engl. lipoteichoic acid, LTA) iz adhezijske
sastavnice biofilma (engl. Biofilm
Adhesion Component, BAC) iz
_Streptococcus uberis_
, soj 5616 ................................................ ≥ 1 RPU*
*relativne jedinice potencije (engl. Relative Potency Units) (ELISA)
ADJUVANS:
Montanide ISA
............................................................................................................................907,1
mg
Monofosforil lipid A (engl. Monophosphoryl Lipid A, MPLA)
Emulzija za injekciju.
Bijela homogena emulzija.
4.
INDIKACIJE
Za aktivnu imunizaciju zdravih krava i junica radi smanjenja
incidencije kliničkih intramamarnih
infekcija uzrokovanih bakterijom
_Streptococcus uberis_
, smanjenja broja somatskih stanica u uzorcima
mlijeka iz četvrtina vimena pozitivnih na
_Streptococcus uberis_
i smanjenja gubitaka u proizvodnji
mlijeka zbog intramamarnih infekcija uzrokovanih bakterijom
_Streptococcus uberis_
.
Početak imunosti: približno 36 dana nakon druge doze.
Trajanje imunosti: približno prvih 5 mjeseci laktacije.
5.
KONTRAINDIKACIJE
Nema.
16
6.
NUSPOJAVE
Lokalna oteklina veća od 5 cm u promjeru na mjestu injekcije
predstavlja vrlo čestu reakciju nakon
primjene cjepiva. Takva će oteklina nestati ili se jasno smanjiti
kroz 17 dana nakon cijepljenja. Međutim,
u nekim slučajevima, oteklina se može održati kroz 4 tjedna.
Postoji velika vjerojatnost od prolaznog povišenja rektalne
t
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
_ _
DODATAK I
SAŽETAK OPISA SVOJSTAVA
2
1.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
UBAC emulzija za injekciju za goveda
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Jedna doza (2 ml) sadrži:
DJELATNA TVAR:
Lipoteikoična kiselina (engl. lipoteichoic acid, LTA) iz adhezijske
sastavnice biofilma (engl. Biofilm
Adhesion Component, BAC) iz
_Streptococcus uberis_
, soj 5616 ................................................ ≥ 1 RPU*
*relativne jedinice potencije (engl. Relative Potency Units) (ELISA)
ADJUVANS:
Montanide ISA
............................................................................................................................907,1
mg
Monofosforil lipid A (engl. Monophosphoryl Lipid A, MPLA)
Potpuni popis pomoćnih tvari vidi u odjeljku 6.1.
3.
FARMACEUTSKI OBLIK
Emulzija za injekciju.
Bijela homogena emulzija.
4.
KLINIČKE POJEDINOSTI
4.1
CILJNE VRSTE ŽIVOTINJA
Govedo.
4.2
INDIKACIJE ZA PRIMJENU, NAVESTI CILJNE VRSTE ŽIVOTINJA
Za aktivnu imunizaciju zdravih krava i junica radi smanjenja
incidencije kliničkih intramamarnih
infekcija uzrokovanih bakterijom
_Streptococcus uberis_
, smanjenja broja somatskih stanica u uzorcima
mlijeka iz četvrtina vimena pozitivnih na
_Streptococcus uberis_
i smanjenja gubitaka u proizvodnji
mlijeka zbog intramamarnih infekcija uzrokovanih bakterijom
_Streptococcus uberis_
.
Početak imunosti: približno 36 dana nakon druge doze.
Trajanje imunosti: približno prvih 5 mjeseci laktacije.
4.3
KONTRAINDIKACIJE
Nema.
4.4
POSEBNA UPOZORENJA ZA SVAKU OD CILJNIH VRSTA ŽIVOTINJA
Cijepite samo zdrave životinje.
Mora se imunizirati cijelo stado.
Imunizaciju treba smatrati jednim od sastavnih dijelova kompleksnog
programa kontrole infekcija, koji
uključuje sve čimbenike važne za zdravo vime (npr. tehnika mužnje,
upravljanje zasušivanjem i
3
uzgojem,
higijena,
hranidba,
nastambe,
ležišta,
udobnost
krava,
kvaliteta
zraka
i
vode,
nadzor
zdravstvenog stanja) i druge načine upravljanja.
4.5
POSEBNE MJERE OPREZA PRILIKOM PRIMJENE
Posebne mjere opreza prilikom primjene na 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 07-12-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 07-12-2021
Public Assessment Report Public Assessment Report Bulgarian 14-08-2018
Patient Information leaflet Patient Information leaflet Spanish 07-12-2021
Public Assessment Report Public Assessment Report Spanish 14-08-2018
Patient Information leaflet Patient Information leaflet Czech 07-12-2021
Public Assessment Report Public Assessment Report Czech 14-08-2018
Patient Information leaflet Patient Information leaflet Danish 07-12-2021
Public Assessment Report Public Assessment Report Danish 14-08-2018
Patient Information leaflet Patient Information leaflet German 07-12-2021
Public Assessment Report Public Assessment Report German 14-08-2018
Patient Information leaflet Patient Information leaflet Estonian 07-12-2021
Public Assessment Report Public Assessment Report Estonian 14-08-2018
Patient Information leaflet Patient Information leaflet Greek 07-12-2021
Public Assessment Report Public Assessment Report Greek 14-08-2018
Patient Information leaflet Patient Information leaflet English 07-12-2021
Public Assessment Report Public Assessment Report English 14-08-2018
Patient Information leaflet Patient Information leaflet French 07-12-2021
Public Assessment Report Public Assessment Report French 14-08-2018
Patient Information leaflet Patient Information leaflet Italian 07-12-2021
Public Assessment Report Public Assessment Report Italian 14-08-2018
Patient Information leaflet Patient Information leaflet Latvian 07-12-2021
Public Assessment Report Public Assessment Report Latvian 14-08-2018
Patient Information leaflet Patient Information leaflet Lithuanian 07-12-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 07-12-2021
Public Assessment Report Public Assessment Report Lithuanian 14-08-2018
Patient Information leaflet Patient Information leaflet Hungarian 07-12-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 07-12-2021
Public Assessment Report Public Assessment Report Hungarian 14-08-2018
Patient Information leaflet Patient Information leaflet Maltese 07-12-2021
Public Assessment Report Public Assessment Report Maltese 14-08-2018
Patient Information leaflet Patient Information leaflet Dutch 07-12-2021
Public Assessment Report Public Assessment Report Dutch 14-08-2018
Patient Information leaflet Patient Information leaflet Polish 07-12-2021
Public Assessment Report Public Assessment Report Polish 14-08-2018
Patient Information leaflet Patient Information leaflet Portuguese 07-12-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 07-12-2021
Public Assessment Report Public Assessment Report Portuguese 14-08-2018
Patient Information leaflet Patient Information leaflet Romanian 07-12-2021
Public Assessment Report Public Assessment Report Romanian 14-08-2018
Patient Information leaflet Patient Information leaflet Slovak 07-12-2021
Public Assessment Report Public Assessment Report Slovak 14-08-2018
Patient Information leaflet Patient Information leaflet Slovenian 07-12-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 07-12-2021
Public Assessment Report Public Assessment Report Slovenian 14-08-2018
Patient Information leaflet Patient Information leaflet Finnish 07-12-2021
Public Assessment Report Public Assessment Report Finnish 14-08-2018
Patient Information leaflet Patient Information leaflet Swedish 07-12-2021
Public Assessment Report Public Assessment Report Swedish 14-08-2018
Patient Information leaflet Patient Information leaflet Norwegian 07-12-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 07-12-2021
Patient Information leaflet Patient Information leaflet Icelandic 07-12-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 07-12-2021

View documents history